Efficacy of Hydroxyurea in Transfusion- Dependent Major β-Thalassemia Patients: A Meta-Analysis

被引:9
作者
Hatamleh, Modather I. [1 ]
Chenna, Venkata Sai Harshabhargav [2 ]
Contractor, Hazel [3 ]
Mohan, Gautham Varun Krishna [4 ]
Tirumandyam, Gayathri [5 ]
Dammas, Nada [6 ]
Khan, Muhammad Waqas [7 ]
Hirani, Shamsha [8 ]
机构
[1] King Abdullah Univ Hosp, Internal Med, Amman, Jordan
[2] Univ Perpetual Help Syst Dalta, Med, Las Pinas, Philippines
[3] Smt Nathiba Hargovandas Lakhmichand NHL Municipal, Med Educ, Ahmadabad, Gujarat, India
[4] Tirunelveli Med Coll, Internal Med, Tirunelveli, Gujarat, India
[5] Dr NTR Univ Hlth Sci, Siddhartha Med Coll, Internal Med, Vijaywada, India
[6] King Faisal Specialist Hosp & Res Ctr, Pediat, Riyadh, Saudi Arabia
[7] Serv Inst Med Sci, Med, Lahore, Pakistan
[8] Baqai Hosp, Cardiol, Karachi, Pakistan
关键词
meta-analysis; transfusion; efficacy; hydroxyurea; transfusion-dependent 13-thalassemia patient; BLOOD;
D O I
10.7759/cureus.38135
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present meta-analysis was conducted to determine the efficacy of hydroxyurea in patients with transfusion dependent major 13-thalassemia. The present meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines. A systematic search was carried out to evaluate the efficacy of hydroxyurea in patients with transfusion-dependent B-thalassaemia using electronic databases, including MEDLINE, Cochrane Central Register of Controlled Trials, and EMBASE. The keywords used to search for relevant studies included "hydroxyurea", "thalassemia", "transfusion-dependent", and "efficacy". Outcomes assessed in the present meta-analysis included transfusion in one year and intervals between transfusions (in days). Other outcomes assessed in the present meta-analysis were fetal hemoglobin (%), hemoglobin (%), and ferritin levels (ng/dl). Total of five studies were included in the analysis enrolling 294 patients with major B-thalassemia. The pooled analysis reported that the mean interval between transfusions was significantly higher in patients receiving hydroxyurea compared to those not receiving hydroxyurea (mean deviation {MD}: 10.07, 95% CI: 2.16, 17.99). Hemoglobin was significantly higher in patients receiving hydroxyurea compared to its counterparts (MD: 1.71, 95% CI: 0.84, 2.57). Patients receiving hydroxyurea had significantly lower ferritin levels compared to those not receiving hydroxyurea (MD:-299.65, 95% CI:-518.35,-80.96). These findings suggest that hydroxyurea may be a promising and cost-effective alternative to blood transfusions and iron chelation therapies for beta-thalassemia patients. However, the authors noted that further randomized controlled trials are needed to validate these findings and to determine the optimal dosages and treatment regimens for hydroxyurea in this patient population.
引用
收藏
页数:8
相关论文
共 24 条
[1]   Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion- Dependent Beta-Thalassemia Major at Zhob, Balochistan [J].
Akram, Sumera ;
Khattak, Saeed Akhtar Khan ;
Khan, Muhammad A. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
[2]  
Algiraigri Ali H, 2017, Hematol Oncol Stem Cell Ther, V10, P116, DOI 10.1016/j.hemonc.2017.02.002
[3]   Successful use of hydroxyurea in beta-thalassemia major [J].
Arruda, VR ;
Lima, CSP ;
Saad, STO ;
Costa, FF .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :964-964
[4]   Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010 [J].
Baronciani, D. ;
Angelucci, E. ;
Potschger, U. ;
Gaziev, J. ;
Yesilipek, A. ;
Zecca, M. ;
Orofino, M. G. ;
Giardini, C. ;
Al-Ahmari, A. ;
Marktel, S. ;
de la Fuente, J. ;
Ghavamzadeh, A. ;
Hussein, A. A. ;
Targhetta, C. ;
Pilo, F. ;
Locatelli, F. ;
Dini, G. ;
Bader, P. ;
Peters, C. .
BONE MARROW TRANSPLANTATION, 2016, 51 (04) :536-541
[5]   Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients [J].
Bordbar, Mohammad Reza ;
Silavizadeh, Samir ;
Haghpanah, Sezaneh ;
Kamfiroozi, Roza ;
Bardestani, Marzieh ;
Karimi, Mehran .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2014, 16 (06)
[6]   A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? [J].
Cappellini, Maria Domenica ;
Porter, John B. ;
Viprakasit, Vip ;
Taher, Ali T. .
BLOOD REVIEWS, 2018, 32 (04) :300-311
[7]   Hematological responses to hydroxyurea therapy in multitransfused thalassemic children [J].
Choudhry V.P. ;
Lal A. ;
Pati H.P. ;
Arya L.S. .
The Indian Journal of Pediatrics, 1997, 64 (3) :395-398
[8]   Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells [J].
Cokic, Vladan P. ;
Andric, Silvana A. ;
Stojilkovic, Stanko S. ;
Noguchi, Constance T. ;
Schechter, Alan N. .
BLOOD, 2008, 111 (03) :1117-1123
[9]   Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia hemoglobin E disease [J].
Fucharoen, S ;
Siritanaratkul, N ;
Winichagoon, P ;
Chowthaworn, J ;
Siriboon, W ;
Muangsup, W ;
Chaicharoen, S ;
Poolsup, N ;
Chindavijak, B ;
Pootrakul, P ;
Piankijagum, A ;
Schechter, AN ;
Rodgers, GP .
BLOOD, 1996, 87 (03) :887-892
[10]   A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger [J].
Mabaera, Rodwell ;
West, Rachel J. ;
Conine, Sarah J. ;
Macari, Elizabeth R. ;
Boyd, Chelsea D. ;
Engman, Cocav A. ;
Lowrey, Christopher H. .
EXPERIMENTAL HEMATOLOGY, 2008, 36 (09) :1057-1072